10 completed, 5 terminated, 5 unknown, 2 withdrawn. 24 Phase 2, 4 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 24 | Completed 10, Terminated 5, Unknown 5, Withdrawn 2, Not yet recruiting 1, Recruiting 1 |
| Phase 1 | 4 | Completed 1, Terminated 1, Unknown 1, Withdrawn 1 |
| Phase 3 | 1 | Withdrawn 1 |
Follow Squamous Cell Lung Cancer: new trials by email Literature Review of Squamous Cell Lung Cancer trials Research Report on Squamous Cell Lung Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase II Study of Platinum (Cisplatin/Carboplatin)and Polymeric Micelles Paclitaxel(Pm-Pac) With Ivonescimab in First Line Metastatic Squamous NSCLC. Ivonescimab 20mg/kg intravenous every 3 weeks - Squamous Cell Lung Cancer | Phase 2 | Not yet recruiting | Jiangsu Cancer Institute & Hospital | 38 | 2025-06-01 | 2025-06-08 |
| CISH Inactivated TILs in the Treatment of NSCLC Fludarabine, Cyclophosphamide, CISH Inactivated TIL - Carcinoma, Non-Small-Cell Lung, Metastatic Non Small Cell Lung Cancer | Phase 1 / Phase 2 | Withdrawn | Intima Bioscience, Inc. | 2023-02-01 | 2026-02-23 | |
| A Study of ZEN003694 in People With Squamous Cell Lung Cancer ZEN003694 - Squamous Cell Lung Cancer | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 13 | 2022-11-01 | 2026-09-23 |
| Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors Neoantigen specific TCR-T cell drug product, Aldesleukin (IL-2) - Gynecologic Cancer, Colorectal Cancer | Phase 1 / Phase 2 | Terminated | Alaunos Therapeutics | 8 | 2022-04-04 | 2025-11-10 |
| Efficacy of Immunotherapy Plus a Drug in Patients With Progressive Advanced Mucosal Cancer of Different Locations pembrolizumab; vorinostat - Squamous Cell Lung Cancer, Vulvar Cancer | Phase 2 | Completed | UNICANCER | 112 | 2020-10-28 | 2025-02-19 |
| FGFR Inhibitor in FGFR Dysregulated Cancer ERDAFITINIB - Lung Cancer, NSCLC | Phase 2 | Terminated | Lung Cancer Group Cologne | 22 | 2019-03-25 | 2023-06-09 |
| Photodynamic Therapy for the Prevention of Lung Cancer Photodynamic Therapy (PDT) - Squamous Cell Lung Cancer, Lung Cancer | Phase 2 / Phase 3 | Withdrawn | University College, London | 2018-09-01 | 2019-02-01 | |
| Necitumumab in the Neoadjuvant Setting With Gemcitabine in Surgically Resectable - 14X-US-I001 Necitumumab-Gemcitabine-Cisplatin, Evaluation to determine if patient is a candidate to proceeed with surgical resection or not - Squamous Cell Lung Cancer | Phase 2 | Terminated | Montefiore Medical Center | 1 | 2018-05-29 | 2020-03-18 |
| Single Agent Chemotherapy +/- Nivolumab in Patients With Advanced Squamous or Non-squamous NSCLC With Primary Resistance to Prior PD-1 or PDL-1 Inhibitor Docetaxel, Nivolumab, Gemcitabine - Non-Squamous Non-Small Cell Lung Cancer (NSCLC), Adenocarcinoma of the Lung | Phase 2 | Terminated | Nasser Hanna, M.D. | 3 | 2017-01-27 | 2022-07-11 |
| A Study of Pemetrexed Plus Cisplatin With Concurrent Radiation Therapy Followed by Docetaxel Consolidation in Patients With Inoperable Squamous Cell Lung Cancer pemetrexed, cisplatin, thoracic radiation therapy - Squamous Cell Lung Cancer | Phase 2 | Unknown | First People's Hospital of Hangzhou | 54 | 2016-10-01 | 2016-11-25 |
| A Trial With Metronomic Low-dose Treosulfan, Pioglitazone and Clarithromycin Versus Standard Treatment in NSCLC Pioglitazone, nivolumab, Treosulfan - Squamous Cell Lung Cancer, Non-Squamous Cell Lung Cancer | Phase 2 | Unknown | University Hospital Regensburg | 86 | 2016-01-01 | 2018-01-18 |
| A Study of AZD2014 in Combination With Selumetinib in Patients With Advanced Cancers AZD2014, AZD6244 - Triple-Negative Breast Cancer, Squamous Cell Lung Cancer | Phase 1 / Phase 2 | Unknown | Queen Mary University of London | 118 | 2015-06-01 | 2020-02-25 |
| Icotinib for Completed Resected IB NSCLC With EGFR Mutation Icotinib - Lung Neoplasms, Squamous Cell Lung Cancer | Phase 2 | Completed | Sun Yat-sen University | 128 | 2015-01-01 | 2024-09-25 |
| Study of Gemcitabine/Carboplatin First-line Chemotherapy +/- Apatorsen in Advanced Squamous Cell Lung Cancers Apatorsen (OGX-427), Gemcitabine, Carboplatin - Squamous Cell Lung Cancer | Phase 2 | Unknown | Queen Mary University of London | 140 | 2014-06-01 | 2017-08-22 |
| Nintedanib in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Up to Two Previous Chemotherapy Regimens nintedanib - Recurrent Non-small Cell Lung Cancer, Squamous Cell Lung Cancer | Phase 2 | Completed | Roswell Park Cancer Institute | 6 | 2014-01-30 | 2017-06-08 |
| Docetaxel With or Without FGFR Inhibitor AZD4547 in Treating Patients With Recurrent Non-Small Cell Lung Cancer docetaxel, AZD4547 - Recurrent Non-small Cell Lung Cancer, Squamous Cell Lung Cancer | Phase 1 / Phase 2 | Completed | ECOG-ACRIN Cancer Research Group | 2 | 2014-01-15 | 2023-06-29 |
| Clinical Trial of Boanmycin Hydrochloride With Docetaxel for Patients With Lung Squamous Cell Cancer as Chemotherapy Boanmycin, Docetaxel - Squamous Cell Lung Cancer | Phase 2 | Unknown | Tianjin Medical University Cancer Institute and Hospital | 300 | 2012-08-01 | 2015-12-22 |
| Dasatinib in Advanced Squamous Cell Lung Cancer Dasatinib - Squamous Cell Lung Cancer | Phase 2 | Terminated | Dana-Farber Cancer Institute | 5 | 2011-09-01 | 2014-07-15 |
| Docetaxel, Cisplatin, Pegfilgrastim, and Erlotinib Hydrochloride in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer cisplatin, pegfilgrastim, erlotinib hydrochloride - Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer | Phase 2 | Completed | Wake Forest University Health Sciences | 45 | 2007-07-01 | 2018-06-29 |
| Radiation Therapy, Bevacizumab, Paclitaxel, and Carboplatin in Treating Patients With Unresectable Stage IIIB or Stage IV Non-Small Cell Lung Cancer at High Risk for Hemoptysis Caused by Bevacizumab bevacizumab, paclitaxel, carboplatin - Adenosquamous Cell Lung Cancer, Drug/Agent Toxicity by Tissue/Organ | Phase 2 | Completed | National Cancer Institute (NCI) | 72 | 2006-10-01 | 2013-01-17 |
Showing 20 of 24. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (14) · Adenocarcinoma of Lung (9) · Lung Neoplasms (5) · Adenocarcinoma, Bronchiolo-Alveolar (3) · Anus Neoplasms (1) · Bronchial Neoplasms (1) · Carcinoma, Squamous Cell (1) · Cholangiocarcinoma (1) · Colorectal Neoplasms (1) · Drug-Related Side Effects and Adverse Reactions (1) · Endometrial Neoplasms (1) · Hemoptysis (1) · Neoplasm Metastasis (1) · Neoplasms, Squamous Cell (1) · Ovarian Neoplasms (1)
Neoplasms (20) · Neoplasms by Site (19) · Lung Diseases (17) · Respiratory Tract Diseases (17) · Respiratory Tract Neoplasms (17) · Thoracic Neoplasms (17) · Carcinoma, Bronchogenic (14) · Bronchial Neoplasms (13) · Lung Neoplasms (12) · Carcinoma (10) · Neoplasms by Histologic Type (10) · Neoplasms, Glandular and Epithelial (10) · Adenocarcinoma (9) · Digestive System Diseases (2) · Digestive System Neoplasms (2)
Docetaxel (6) · Carboplatin (3) · Paclitaxel (3) · Taxes (3) · Bevacizumab (2) · Cetuximab (2) · Cisplatin (2) · Erlotinib Hydrochloride (2) · Gemcitabine (2) · Interleukin-2 (2) · Nivolumab (2) · Pemetrexed (2) · Radiation (2) · Radiotherapy (2) · aldesleukin (2)
National Cancer Institute (NCI) (5) · Queen Mary University of London (2) · Alaunos Therapeutics (1) · Dana-Farber Cancer Institute (1) · ECOG-ACRIN Cancer Research Group (1) · First People's Hospital of Hangzhou (1) · Intima Bioscience, Inc. (1) · Jiangsu Cancer Institute & Hospital (1) · Lung Cancer Group Cologne (1) · Memorial Sloan Kettering Cancer Center (1) · Montefiore Medical Center (1) · Nasser Hanna, M.D. (1) · Roswell Park Cancer Institute (1) · Sun Yat-sen University (1) · Tianjin Medical University Cancer Institute and Hospital (1)
United States (13) · China (3) · Germany (2) · United Kingdom (2) · France (1)
Bruce Johnson, MD (1) · Charles Rudin (1) · Christophe Le Tourneau, MD (1) · Edward Kim (1) · Emil Lou, MD, PhD (1) · Erminia Massarelli, MD, PhD, MS (1) · Hongbin Chen (1) · Lucia Nogova, MD (1) · Nasser Hanna, M.D. (1) · Neal Ready (1) · Paul Hesketh (1) · Paul Paik, MD (1) · Peng Chen, M.D. (1) · Peter Schmid, Prof. (1) · Peter Schmid, Professor (1)
PMID 10811675, PMID 11784875, PMID 11870177, PMID 16043828, PMID 16425523, PMID 17167137, PMID 19410716, PMID 24100924, PMID 24128713, PMID 35537408, PMID 36816343, PMID 40588522, PMID 41468684, PMID 7580546, PMID 7884425
U10CA031946 (2), U10CA032102 (2), 2014 (1), 2018 (1), 2019 (1), N01CM62201 (1), N01CM62203 (1), N01CM62208 (1), N01CM62209 (1), P30CA016056 (1), U10CA021115 (1)